Professor Anton Berns
Professor Anton Berns is Director of Research at the Netherlands Cancer Institute.

"The relationship with CRT has helped us enormously in evaluating and securing our intellectual property. In addition, CRT’s worldwide contacts with the biotechnology and pharmaceutical industry make it possible to exploit our discoveries in such a way that it will benefit cancer patients.
We are looking forward to working with them in the years to come."

Professor Steve Jackson
Steve Jackson is Professor of Biology at the University of Cambridge and Deputy Chairman of the Wellcome Trust/Cancer Research UK Institute. He is also Chief Scientific Officer at KuDOS Pharmaceuticals Ltd.

"I would say that CRT was very far sighted to realise that a company like KuDOS, rather than a large pharmaceutical company, was the best vehicle to maximise the clinical promise of PaTrin-2. It is clear that CRT licensed it to us for commercial reasons, because KuDOS has the right skill set to get the most out of PaTrin-2 and deliver its full clinical potential."

"Just the fact that you are linked to CRT, and therefore to Cancer Research UK, gives you a pedigree, making it easier to approach collaborators, companies or investors.We have established a very productive and symbiotic relationship with CRT, which I hope that we can maintain."

Mr. Nick Adams
Nick is Business Development Director with Antisoma Research Ltd.

"They’re a great bunch of people, very easy to get on with. They’re bright and bring me a lot of interesting technologies. They’ve done very well in finding technologies not only in their own laboratories but also in research institutes and universities across Europe. What’s more, they have a policy of only bringing products or technologies that have good intellectual property protection. That’s very important."

Dr Roy Bicknell
Dr Bicknell is head of the Cancer Research UK Angiogenesis Laboratory at the Institute of Molecular Medicine of Oxford University.

"We can’t do everything alone because we’re a basic research laboratory. We work with the CRT Development Laboratory to take a potential therapy further and then, if it still looks promising, to partner with industry."

"CRT are a respected organisation recognised as the leading intellectual property company for cancer in Europe. For CRT to contact a company carries a lot more weight than if I were to do so directly."